Status:
COMPLETED
Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Invasive Breast Carcinoma
Eligibility:
FEMALE
18+ years
Brief Summary
This trial studies the barriers associated with timely chemotherapy given after surgery (adjuvant) in patients with invasive breast cancer. Meeting with patients and asking questions may help doctors ...
Detailed Description
PRIMARY OBJECTIVES: I. To comprehensively and qualitatively assess and identify the determinants of time to chemotherapy (TTC) delays in a vulnerable population using qualitative methods. Ia. To des...
Eligibility Criteria
Inclusion
- Diagnosed with primary invasive breast cancer
- For patients receiving adjuvant chemotherapy: First dose of chemotherapy administered \>= 60 days after definitive breast cancer surgery. For patient treated with neoadjuvant chemotherapy: First dose of chemotherapy administered \>= 60 days after pathological diagnosis
- Diagnosis of breast cancer within three years of study enrollment
- Can speak, read, and understand English and/or Spanish
- Patient of Lyndon B. Johnson General Hospital-Harris Health System (LBJ-HHS) or MD Anderson Cancer Center
Exclusion
- Women hospitalized for a critical condition or who are considered medically unstable by their medical team
- Patients that started chemotherapy \>= 3 years after definitive breast cancer surgery
Key Trial Info
Start Date :
August 23 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 16 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04087057
Start Date
August 23 2019
End Date
April 16 2024
Last Update
April 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030